missing translation for 'onlineSavingsMsg'
Learn More
Tocris Bioscience™ RAGE 229 Product Code.: 18787446

Tocris Bioscience™ RAGE 229
GREENER_CHOICE

Product Code. 18787446
5 mg, 5mg
Click to view available options
Quantity:
5 mg
Unit Size:
5mg
This item is not returnable. View return policy

Product Code. 18787446

Brand: Tocris Bioscience™ 7701/5

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

ctRAGE-DIAPH1 interaction antagonist; reduces inflammatory signaling in diabetic mice

RAGE 229 is an antagonist of the interaction between the cytoplasmic tail of the receptor for advanced glycation end products (ctRAGE) and the formin, Diaphanous-1 (DIAPH1) (KD for binding to ctRAGE = 2 nM). RAGE 229 inhibits the migration of human aortic smooth muscle cells in an in vitro wound healing assay (IC50 = 120 nM). RAGE 229 reduces short- and long-term complications of diabetes in mouse models, without lowering blood glucose concentrations. RAGE 229 also reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 and attenuates inflammatory signaling in diabetic mice.
Greener Choice Claims
  • Environmental benefits include:
    • Ozone-Safe or Safe for the Ozone Layer
TRUSTED_SUSTAINABILITY

Specifications

Chemical Name or Material N-[4-[7-Cyano-4-(4-morpholinylmethyl)-2-quinolinyl]phenyl]acetamide
CAS 2143072-85-7
Quantity 5 mg
Target AGER
Molecular Formula C23H22N4O2
Purity 0.98
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title
Tocris Bioscience™ RAGE 229 >

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.